Literature DB >> 18556334

Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study.

Peter G Scheffer1, Tom Teerlink, Jacqueline M Dekker, Griët Bos, Giel Nijpels, Michaela Diamant, Piet J Kostense, Coen D A Stehouwer, Robert J Heine.   

Abstract

BACKGROUND: Hypertriglyceridemia is a cardiovascular risk factor. Apolipoprotein C-III (apoC-III) is an important determinant of the catabolic rate of triglyceride-rich lipoproteins. The aim of this study was to investigate the prognostic value of plasma apoC-III concentrations for cardiovascular mortality.
METHODS: We performed this prospective study in 2244 subjects (ages 49-77 years) who participated in the Hoorn Study. During a mean follow-up of 15 years, 504 individuals died: 231 of cardiovascular disease, 180 of cancer, and 93 of other causes. Cardiovascular disease risk factors and plasma apoC-III concentrations were measured at baseline.
RESULTS: The age- and sex-adjusted plasma apoC-III concentration was prospectively associated with cardiovascular mortality (P < 0.001). After adjustment for traditional risk factors, including fasting triglycerides, the hazard ratio (95% CI) for cardiovascular death between the highest and the lowest quartile of apoC-III was 1.85 (1.02-3.38). High concentrations of apoC-III did not appear to be associated with noncardiovascular mortality.
CONCLUSIONS: In this general population cohort, a high apoC-III concentration in plasma, independently of fasting triglycerides and other traditional risk factors, predicts cardiovascular mortality.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18556334     DOI: 10.1373/clinchem.2008.103234

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  22 in total

1.  Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes.

Authors:  Helen C Looker; Marco Colombo; Felix Agakov; Tanja Zeller; Leif Groop; Barbara Thorand; Colin N Palmer; Anders Hamsten; Ulf de Faire; Everson Nogoceke; Shona J Livingstone; Veikko Salomaa; Karin Leander; Nicola Barbarini; Riccardo Bellazzi; Natalie van Zuydam; Paul M McKeigue; Helen M Colhoun
Journal:  Diabetologia       Date:  2015-03-05       Impact factor: 10.122

2.  Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.

Authors:  Julian C van Capelleveen; Sophie J Bernelot Moens; Xiaohong Yang; John J P Kastelein; Nicholas J Wareham; Aeilko H Zwinderman; Erik S G Stroes; Joseph L Witztum; G Kees Hovingh; Kay-Tee Khaw; S Matthijs Boekholdt; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-05-04       Impact factor: 8.311

3.  Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.

Authors:  Ann C Skulas-Ray; Petar Alaupovic; Penny M Kris-Etherton; Sheila G West
Journal:  J Clin Lipidol       Date:  2014-12-11       Impact factor: 4.766

Review 4.  Lipid effects of endocrine medications.

Authors:  Dan V Mihailescu; Avni Vora; Theodore Mazzone
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

5.  Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.

Authors:  Julian C van Capelleveen; Sang-Rok Lee; Rutger Verbeek; John J P Kastelein; Nicholas J Wareham; Erik S G Stroes; G Kees Hovingh; Kay-Tee Khaw; S Matthijs Boekholdt; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Clin Lipidol       Date:  2018-08-29       Impact factor: 4.766

6.  Lack of association between apolipoprotein C3 gene polymorphisms and risk of coronary heart disease in a Han population in East China.

Authors:  Juan Yu; Jingjing Huang; Yan Liang; Baodong Qin; Su He; Jing Xiao; Huimin Wang; Renqian Zhong
Journal:  Lipids Health Dis       Date:  2011-11-04       Impact factor: 3.876

7.  Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells.

Authors:  E-ri M Sol; Tea Sundsten; Peter Bergsten
Journal:  Lipids Health Dis       Date:  2009-02-05       Impact factor: 3.876

8.  Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.

Authors:  O Samuelsson; P O Attman; I Gause-Nilsson; M K Svensson; P Alaupovic
Journal:  PPAR Res       Date:  2013-03-28       Impact factor: 4.964

9.  Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion.

Authors:  Chunyu Zheng; Veronica Azcutia; Elena Aikawa; Jose-Luiz Figueiredo; Kevin Croce; Hiroyuki Sonoki; Frank M Sacks; Francis W Luscinskas; Masanori Aikawa
Journal:  Eur Heart J       Date:  2012-08-26       Impact factor: 29.983

10.  Biotechnology Approaches for the Treatment of Dyslipidemia.

Authors:  Cinzia Parolini
Journal:  Cardiovasc Drugs Ther       Date:  2021-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.